Piper Jaffray downgraded Sarepta Therapeutic (NASDAQ: SRPT) from Neutral to Underweight with a price target of $6.00 (from $15.00).Analyst Edward ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE